Metastatic uveal melanoma: Is there a role for conventional chemotherapy? - A single center study based on 58 patients

Melanoma Research

Volumn 21, Issue 3, 2011, Pages 217-222

  Pons, Francesc ^a   Plana, Maria ^a   Caminal, Josep Maria ^a   Pera, Joan ^a   Fernandes, Isabel ^b   Perez, Javier ^a   Garcia Del Muro, Xavier ^a   Marcoval, Joaquim ^a   Penin, Rosa ^a   Fabra, Angels ^a   Piulats, Josep Maria ^a  

^a HOSPITAL UNIVERSITARI DE BELLVITGE   (Spain)

^b HOSPITAL DE SANTA MARIA   (Portugal)

Author keywords

best supportive care; chemotherapy; liver metastasis; uveal melanoma

Indexed keywords

ALPHA INTERFERON; CARBOPLATIN; DACARBAZINE; FOTEMUSTINE; INTERLEUKIN 2; TEMOZOLOMIDE;

ADULT; AGED; ARTICLE; CANCER CHEMOTHERAPY; CANCER PATIENT; CANCER SURVIVAL; FEMALE; HUMAN; LIVER METASTASIS; MAJOR CLINICAL STUDY; MALE; METASTASIS; OVERALL SURVIVAL; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SYSTEMIC THERAPY; UVEA MELANOMA;

EID: 79955578782     PISSN: 09608931     EISSN: None     Source Type: Journal    
DOI: 10.1097/CMR.0b013e3283457726     Document Type: Article

References (24)

1. Osterlind A. Trends in incidence of ocular malignant melanoma in Denmark 1943-1982. Int J Cancer 1987; 40:161-164. (Pubitemid 17126124)
2. Eskelin S, Pyrhonen S, Hahka-Kemppinen M, Tuomaala S, Kivela T. A prognostic model and staging for metastatic uveal melanoma. Cancer 2003; 97:465-475. (Pubitemid 36133814)
3. Bakalian S, Marshall JC, Logan P, Faingold D, Maloney S, Di Cesare S, et al. Molecular pathways mediating liver metastasis in patients with uveal melanoma. Clin Cancer Res 2008; 14:951-956. (Pubitemid 351302538)
4. Mariani P, Piperno-Neumann S, Servois V, Berry MG, Dorval T, Plancher C, et al. Surgical management of liver metastases from uveal melanoma: 16 years' experience at the Institut Curie. Eur J Surg Oncol 2009; 35:1192-1197.
5. Bedikian AY, Johnson MM, Warneke CL, Papadopoulos NE, Kim K, Hwu WJ, et al. Prognostic factors that determine the long-term survival of patients with unresectable metastatic melanoma. Cancer Invest 2008; 26:624-633. (Pubitemid 351918588)
6. Rivoire M, Kodjikian L, Baldo S, Kaemmerlen P, Negrier S, Grange JD. Treatment of liver metastases from uveal melanoma. Ann Surg Oncol 2005; 12:422-428. (Pubitemid 40884256)
7. Schmittel A, Schmidt-Hieber M, Martus P, Bechrakis NE, Schuster R, Siehl JM, et al. A randomized phase II trial of gemcitabine plus treosulfan versus treosulfan alone in patients with metastatic uveal melanoma. Ann Oncol 2006; 17:1826-1829. (Pubitemid 44884059)
8. Pyrhonen S, Hahka-Kemppinen M, Muhonen T, Nikkanen V, Eskelin S, Summanen P, et al. Chemoimmunotherapy with bleomycin, vincristine, lomustine, dacarbazine (BOLD), and human leukocyte interferon for metastatic uveal melanoma. Cancer 2002; 95:2366-2372. (Pubitemid 35351144)
9. Becker JC, Terheyden P, Kampgen E, Wagner S, Neumann C, Schadendorf D, et al. Treatment of disseminated ocular melanoma with sequential fotemustine, interferon alpha, and interleukin 2. Br J Cancer 2002; 87: 840-845. (Pubitemid 35252958)
10. Bedikian AY, Papadopoulos N, Plager C, Eton O, Ring S. Phase II evaluation of temozolomide in metastatic choroidal melanoma. Melanoma Res 2003; 13:303-306. (Pubitemid 36683775)
11. Peters S, Voelter V, Zografos L, Pampallona S, Popescu R, Gillet M, et al. Intra-arterial hepatic fotemustine for the treatment of liver metastases from uveal melanoma: experience in 101 patients. Ann Oncol 2006; 17:578-583.
12. Bedikian AY, Legha SS, Mavligit G, Carrasco CH, Khorana S, Plager C, et al. Treatment of uveal melanoma metastatic to the liver: a review of the M.D. Anderson Cancer Center experience and prognostic factors. Cancer 1995; 76:1665-1670.
13. Flaherty LE, Unger JM, Liu PY, Mertens WC, Sondak VK. Metastatic melanoma from intraocular primary tumors: the Southwest Oncology Group experience in phase II advanced melanoma clinical trials. Am J Clin Oncol 1998; 21:568-572. (Pubitemid 28558346)
14. De Waard-Siebinga I, Creyghton WM, Kool J, Jager MJ. Effects of interferon alfa and gamma on human uveal melanoma cells in vitro. Br J Ophthalmol 1995; 79:847-855.
15. Bedikian AY. Metastatic uveal melanoma therapy: current options. Int Ophthalmol Clin 2006; 46:151-166. (Pubitemid 44124237)
16. Ives NJ, Stowe RL, Lorigan P, Wheatley K. Chemotherapy compared with biochemotherapy for the treatment of metastatic melanoma: a meta-analysis of 18 trials involving 2621 patients. J Clin Oncol 2007; 25: 5426-5434. (Pubitemid 350232219)
17. Quinten C, Coens C, Mauer M, Comte S, Sprangers MA, Cleeland C, et al. Baseline quality of life as a prognostic indicator of survival: a meta-analysis of individual patient data from EORTC clinical trials. Lancet Oncol 2009; 10:865-871.
18. Coleman K, Baak JP, Van Diest P, Mullaney J, Farrell M, Fenton M. Prognostic factors following enucleation of 111 uveal melanomas. Br J Ophthalmol 1993; 77:688-692. (Pubitemid 23326053)
19. Schmittel A, Bechrakis NE, Martus P, Mutlu D, Scheibenbogen C, Bornfeld N, et al. Independent prognostic factors for distant metastases and survival in patients with primary uveal melanoma. Eur J Cancer 2004; 40:2389-2395. (Pubitemid 39424951)
20. Gragoudas ES, Egan KM, Seddon JM, Glynn RJ, Walsh SM, Finn SM, et al. Survival of patients with metastases from uveal melanoma. Ophthalmology 1991; 98:383-389. Discussion 390.
21. Kodjikian L, Grange JD, Baldo S, Baillif S, Garweg JG, Rivoire M. Prognostic factors of liver metastases from uveal melanoma. Graefes Arch Clin Exp Ophthalmol 2005; 243:985-993. (Pubitemid 41631038)
22. Leyvraz S, Spataro V, Bauer J, Pampallona S, Salmon R, Dorval T, et al. Treatment of ocular melanoma metastatic to the liver by hepatic arterial chemotherapy. J Clin Oncol 1997; 15:2589-2595. (Pubitemid 27289889)
23. Triozzi PL, Eng C, Singh AD. Targeted therapy for uveal melanoma. Cancer Treat Rev 2008; 34:247-258.
24. Van Raamsdonk CD, Bezrookove V, Green G, Bauer J, Gaugler L, O'Brien JM, et al. Frequent somatic mutations of GNAQ in uveal melanoma and blue naevi. Nature 2009; 457:599-602.